证券简称：国新健康 证券代码：000503 编号：2025-60 国新健康保障服务集团股份有限公司 关于召开 2025 年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 本次股东大会的议案 1 至议案 3 需经出席会议的股东所持表决权的三分之 二以上通过，其他议案需经出席会议的股东所持表决权的二分之一以上通过。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 10 月 14 日召开第十二届董事会第四次会议，审议通过了《关于召开公司 2025 年第 二次临时股东大会的议案》公司已于 2025 年 10 月 15 日在《中国证券报》《上 海证券报》《证券时报》及巨潮资讯网（网址：www.cninfo.com.cn）发布了《关 于召开 2025 年第二次临时股东大会的通知》（公告编号：2025-59）。为了保护 投资者的合法权益，方便公司股东行使股东大会表决权，现发布关于召开 2025 年第二次临时股东大会的提示性公告。具体内容公告如下： 一、召开会议的基本情况 （一）股东大会届次：2025 年第二次 ...

Core Viewpoint - Guoxin Health is actively collaborating with insurance brokerage firms, health management service providers, and medical service institutions to explore a data-driven full-chain service model for health insurance, covering product design, marketing, underwriting, claims, and risk control [2] Group 1: Collaboration and Innovation - The company has established deep cooperative relationships with several domestic insurance companies to promote the implementation of innovative health insurance service models [2] - Guoxin Health is involved in projects such as the operation of public data authorization in Hangzhou and the personal medical insurance data authorization query in Pingxiang, Jiangxi, to enhance data compliance and operational practices [2] Group 2: Data Integration and Development - Guoxin Health has jointly established a company with Hubei Data Group to operate health medical big data in Central China, aiming to integrate and utilize health medical data resources within Hubei Province [2] - The newly formed company serves as a pilot for public data authorization operations in the "Three Medical" fields, facilitating the development and utilization of health medical data resources [2]

Core Insights - Guoxin Health aims to enhance comprehensive reform efficiency and improve coordination between front, middle, and back offices to increase work efficiency [2] - The company plans to continue adjusting its business structure, ensuring stable development of its three medical businesses while accelerating growth in data innovation and health service sectors [2] - Guoxin Health is focused on cost reduction and efficiency improvement, striving to maintain revenue growth throughout the year and reduce operational losses [2]

Core Insights - The company focuses on comprehensive management services for medical insurance funds, medical quality and safety services, drug and medical device regulation, and innovative health services [1] Business Coverage - The company's operations have expanded to cover over 200 regions across 29 provinces (autonomous regions and municipalities) in China [1]

Core Insights - Guoxin Health is actively participating in pilot projects under the guidance of national medical insurance data authorities, specifically in Hangzhou [1] - The company is implementing a public data authorization operation mechanism to facilitate the practical application of commercial insurance underwriting and claims scenarios [1] - Currently, the commercial insurance data services provided by the company focus on scenario operation services and do not involve data asset-related matters [1]

Core Insights - Guo Xin Health (000503.SZ) is actively participating in pilot projects under the guidance of national medical insurance data authorities [1] - The company has implemented a public data authorization operation mechanism in Hangzhou to facilitate the practical application of commercial insurance underwriting and claims scenarios [1] - Currently, the commercial insurance data services provided by the company focus on scenario operation services and do not involve data asset-related matters [1]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

Core Insights - The healthcare insurance information system plays a crucial role in managing medical insurance, improving service efficiency, and supporting fund supervision and quality assessment [1][3][8] - The market size of China's healthcare insurance information system is projected to reach 4.8 billion yuan in 2024, reflecting a year-on-year growth of 6.4% [1][8][9] Industry Overview - The healthcare insurance information system is a computer system designed to manage medical insurance operations, including participant management, cost settlement, fund supervision, and data sharing [3][4] - The industry has evolved through four stages, from standalone systems to the current core platform construction phase, driven by technological advancements [4][5] Market Development - The market for healthcare insurance information systems has shown an upward trend, despite delays in construction and acceptance due to the pandemic in 2022 [1][8] - The number of participants in basic medical insurance in China is expected to rise, providing a substantial data foundation for healthcare information systems [7][8] Competitive Landscape - The competition in the healthcare insurance information system industry is intensifying, with the top five companies holding a market share of 36.3% in 2024 [9] - Neusoft Corporation maintains a significant market share of 15.1%, leveraging its early market entry and extensive service capabilities [9][10] Future Trends - The future of healthcare insurance information systems will focus on data sharing, interoperability, and the use of advanced technologies like big data and artificial intelligence to enhance service personalization [11] - Data security and privacy protection will become critical areas of development for the industry [11]

Group 1 - The company announced the election of a new independent director, Mr. Shen Weixing, to ensure the normal operation of the board of directors [1][24][26] - Mr. Shen possesses the necessary qualifications and independence as required by relevant laws and regulations [4][24] - The board meeting held on October 14, 2025, approved the proposal to elect Mr. Shen, pending approval from the shareholders' meeting [1][24][26] Group 2 - The company plans to apply for a comprehensive credit facility of RMB 50 million from several banks to support its daily operations and business development [6][9][11] - The credit facility will have a term of one year, and the company will withdraw funds as needed [6][9] - The board meeting on October 14, 2025, also approved this proposal, which will not adversely affect the company's normal operations [7][9][11] Group 3 - The company will hold its second extraordinary general meeting of 2025 on October 30, 2025, to discuss various proposals [30][31] - The meeting will include voting on the election of the independent director and the proposed amendments to the company's articles of association [30][31][35] - The company has ensured that the meeting complies with all relevant legal and regulatory requirements [31][32]

Market Overview - The SPD sector of medical consumables increased by 1.95% compared to the previous trading day, with Sely Medical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Sely Medical (603716) closed at 26.86, with a rise of 7.31% and a trading volume of 384,800 shares, amounting to a transaction value of 1.02 billion [1] - Other notable stocks include: - East China Pharmaceutical (000963) at 40.86, up 3.89% with a transaction value of 615 million [1] - Kangdelai (603987) at 9.21, up 2.33% with a transaction value of 80.62 million [1] - Longma Information (300288) at 13.95, up 1.90% with a transaction value of 54.30 million [1] Capital Flow - The SPD sector saw a net inflow of 40.98 million from main funds, while retail funds had a net inflow of 14.03 million [2] - Notably, speculative funds experienced a net outflow of 55.01 million [2] Individual Stock Capital Flow - Sely Medical had a main fund net inflow of 71.52 million, but speculative funds saw a net outflow of 38.57 million [3] - Other stocks with significant capital flow include: - Liuyou Group (603368) with a main fund net inflow of 9.20 million and a speculative fund net outflow of 12.49 million [3] - Guoxin Health (000503) with a main fund net inflow of 8.12 million and a speculative fund net inflow of 791,200 [3]